News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 4, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 3, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 3, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 26, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
-- Study will evaluate the safety and preliminary efficacy of AR-13503 SR Implant as monotherapy and in combination with aflibercept -- DURHAM, N.C. --(BUSINESS WIRE)--Aug. 20, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery,
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update
Conference Call and Webcast Today, August 7 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Aug. 7, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 25, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule
  DURHAM, N.C. --(BUSINESS WIRE)--Jul. 9, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 17, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 11, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
TOP